Résumé
The two mechanisms of action of bezafibrate and nicotinic acid and their combination were evaluated in normal rats and triton treated rats. Bezafibrate was effective hypolipidemic agent in normal rats, but addition of nicotinic acid has certainly improved the effectiveness further which could be of clinical significance. In triton treated rats bezafibrate and nicotinic acid used individually and together had prophylactic hypolipidemic action. However, in their therapeutic effectiveness, bezafibrate reduced triglycerides (65.4%) and nicotinic acid, cholesterol (39.3%). But when treated together they showed marked acceleration in the removal of cholesterol as well as triglycerides. It is therefore concluded that a combination of bezafibrate and nicotinic acid may be beneficial in the treatment of hyperlipoproteinemias, both prophylactically and therapeutically.
Sujets)
Animaux , Bézafibrate/administration et posologie , Cholestérol/sang , Association de médicaments , Hyperlipidémies/traitement médicamenteux , Mâle , Acide nicotinique/administration et posologie , Polyéthylène glycols , Rats , Triglycéride/sangRésumé
IDPH-791, a novel centrally acting muscle relaxant, in doses up to 500 mg/kg (po) for 14 days did not result in any appreciable adverse effect on body weight gain, food or water consumption including biochemical and haematologica parameters in rats. Variations observed in the biochemistry and haematology were either comparable to controls or were within normal limits.